BAP1 protein loss by immunohistochemistry: A potentially useful tool for prognostic prediction in patients with uveal melanoma

Pathology

Volumn 45, Issue 7, 2013, Pages 651-656

  Shah, Akeesha A ^a   Bourne, T David ^a   Murali, Rajmohan ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

BAP1; Immunohistochemistry; Metastasis; Pathology; Prognosis; Uveal melanoma

Indexed keywords

BAP1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PILOT STUDY; PROGNOSIS; SURVIVAL RATE; UVEA TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; UVEAL NEOPLASMS;

EID: 84896780820     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000002     Document Type: Article

References (21)

1. Singh AD, Turell ME, Topham AK Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011; 118: 1881-5.
2. Gill HS, Char DH Uveal melanoma prognostication: from lesion size and cell type to molecular class. Can J Ophthalmol 2012; 47: 246-53.
3. Abdel-Rahman M.H., Cebulla CM, Verma V, et al Monosomy 3 status of uveal melanoma metastases is associated with rapidly progressive tumors and short survival. Exp Eye Res 2012; 100: 26-31.
4. Wiesner T, Obenauf AC, Murali R, et al Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011; 43: 1018-21.
5. Harbour JW, Onken MD, Roberson E.D., et al Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010; 330: 1410-3.
6. Wiesner T, Murali R, Fried I., et al A distinct subset of atypical Spitz tumors is characterized byBRAF mutation and loss of BAP1 expression. Am J Surg Pathol 2012; 36: 818-30.
7. Freton A, Chin KJ, Raut R, Tena L.B., Kivela T., Finger PT Initial PET/CT staging for choroidal melanoma: AJCC correlation and second nonocular primaries in 333 patients. Eur J Ophthalmol 2012; 22: 236-43.
8. Freudenberg LS, Schueler AO, Beyer T, et al Whole-body fluorine-18 fluordeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in staging of advanced uveal melanoma. Surv Ophthalmol 2004; 49: 537-40.
9. Modorati G, Lucignani G, Landoni C., et al Glucose metabolism and pathological findings in uveal melanoma: preliminary results. Nucl Med Commun 1996; 17: 1052-6.
10. Frenkel S, Barzel I, Levy J., et al Demonstrating circulation in vasculogenic mimicry patterns of uveal melanoma by confocal indocyanine green angiography. Eye (Lond) 2008; 22: 948-52.
11. Kivela T, Makitie T, Al-Jamal RT, Toivonen P. Microvascular loops and networks in uveal melanoma. Can J Ophthalmol 2004; 39: 409-21.
12. Coleman K, Baak JP, van Diest PJ, Mullaney J. Prognostic value of morphometric features and the callender classification in uveal melanomas. Ophthalmology 1996; 103: 1634-41.
13. Gamel JW, McLean IW, Foster W.D., Zimmerman LE Uveal melanomas: correlation of cytologic features with prognosis. Cancer 1978; 41: 1897-901.
14. McLean IW, Foster WD, Zimmerman L.E., Gamel JW Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol 1983; 96: 502-9.
15. Hayton S, Lafreniere R, Jerry L.M., Temple WJ, Ashley P. Ocular melanoma in Alberta: a 38 year review pointing to the importance of tumor size and tumor histology as predictors of survival. J Surg Oncol 1989; 42: 215-8.
16. Seddon JM, Polivogianis L, Hsieh C.C., Albert DM, Gamel JW, Gragoudas ES Death from uveal melanoma. Number of epithelioid cells and inverse SD of nucleolar area as prognostic factors. Arch Ophthalmol 1987; 105: 801-6.
17. McLean IW, Saraiva VS, Burnier MN Jr. Pathological and prognostic features of uveal melanomas. Can J Ophthalmol 2004; 39: 343-50.
18. Gamel JW, McCurdy JB, McLean IW A comparison of prognostic covariates for uveal melanoma. Invest Ophthalmol Vis Sci 1992; 33: 1919-22.
19. Folberg R, Maniotis AJ Vasculogenic mimicry. APMIS 2004; 112: 508-25.
20. Maniotis AJ, Folberg R, Hess A., et al Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999; 155: 739-52.
21. Onken MD, Worley LA, Ehlers J.P., Harbour JW Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004; 64: 7205-9.